Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

First real-world data show omicron booster kept seniors out of hospitals

In the first real-world test of vaccine boosters specially designed to protect against the omicron variant, Israeli researchers have found that people 65 and over who got an updated jab were 81% less likely to be hospitalized with COVID-19 than those who did not.

Los Angeles Times

Pfizer CEO Dismisses Reports of a Paxlovid Generic for China

The U.S. pharmaceutical giant is working on starting domestic production of the branded version of the Covid drug in the first half of this year

Caixin Global

Pfizer's Paxlovid not included in China's national insurance

China will not include Pfizer’s COVID-19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The Independent UK

Weekly Must-Read: China’s Road to Economic Recovery Faces Post-Covid Speed Bumps

Policymakers are now squarely focused on reviving the economy. But some analysts warned against ‘excessive optimism’ about when pre-pandemic growth rates will return

Caixin Global

Investing Champion Leif Soreide Notes Biotech Stocks May Be Countercyclical

Biotech stocks can often be countercyclical, according to some market experts. We explore some biotech opportunities in this article.

StockNews.com

Tory MP condemns colleague's 'nonsense' claims about Covid vaccines

A TORY MP has been accused of spreading “nonsense” about the Covid vaccine by a senior Conservative colleague.

The National (Scotland)

Read news from The Economist, FT, and more,
with one subscription

1 Stock That Would Be an Excellent Addition to Your Portfolio for Years to Come

Biopharmaceutical company Pfizer (PFE) is committed to executing its strategies to deliver breakthroughs to patients worldwide. The company saw a solid operational performance in the last reported quarter and raised its full-year 2022 outlook. Given PFE’s strong fundamentals and reliable dividends, this stock could be an ideal long-term investment. Read…

StockNews.com

China's COVID vaccines: Do the jabs do the job?

As case counts surge in China, rumors circulate about the effectiveness and safety of the made-in-China vaccines in use there. Here's what we know about CoronaVac and Sinopharm.

WEKU

Top Stories of the Month: Covid Chaos at China’s Hospitals as Stringent Control Policy Eases

Health care centers from Guangzhou to Shijiazhuang and Beijing are slammed amid surging infections and severe shortages of medical workers

Caixin Global

3 Stocks to Help You Get Through Today's Market Fear

Instead of a Santa Claus rally, the market continues to experience volatility at the end of the year with uncertainties surrounding the reopening of the Chinese economy and a looming recession due to seemingly unending interest rate hikes. Given this backdrop, loading up on fundamentally strong stocks Walmart (WMT), Pfizer…

StockNews.com

2 COVID-19 Stocks That Are Still Strong Buys

Given that COVID-19 is here to stay for the foreseeable future, investors could still benefit from their investments in companies that saw record-breaking sales during the pandemic’s height because of the effectiveness of their products in fighting the virus. With the potential resurgence of COVID-19 in several countries, Pfizer (PFE)…

StockNews.com

Getting vaccinated this holiday season? Here’s how to stay up-to-date on your COVID shots

DALLAS — Staying on schedule with the COVID-19 vaccine can feel like chasing a moving target.

Tribune News Service

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Salon

Inside Google's black box ad empire

Reporters uncovered a multi-billion-dollar ad network containing manga piracy, porn, fraud and disinformation

Caixin Global

Weekly Must-Read: Why China’s Exports Are in the Doldrums

Demand has fallen off in recent months in the country’s three biggest markets, though the reasons vary by region

Reuters

The world fears a new China COVID wave, ponders how to help Xi

Officials and global health experts outside China are anxiously watching a COVID-19 surge there, worried a nation of 1.4 billion people is inadequately vaccinated and may not have the healthcare tools to treat a wave of illness expected to kill more than one million people through 2023.

The New Daily

Dr Kerryn Phelps reveals wife’s ‘devastating’ vaccine injury, calls for urgent COVID plan

Dr Kerryn Phelps has spoken out about her wife's "severe" reaction to the COVID jab as she warned about the direction of Australia's current handling of the pandemic.

Get all your
news in one place.

100's of premium titles.
One news app.

Newsroom.co.nz

'Have a safe as summer': Public health measures replaced by advice

A list of advice for avoiding Covid this summer provides a stark contrast to the broad public health messaging of a year ago, despite case numbers being much higher

StockNews.com

The 3 Safest Stocks to Buy in the Market Now

Along with an interest rate hike of 50 bps at the FOMC meeting last week, the Fed officials signaled to continue raising rates through next year, with no expectations to cut rates until 2024. The Fed’s hawkish stance and rising recessionary fears have dampened investor sentiment lately. Given the backdrop,…

WEKU

Coronavirus FAQ: Is Paxlovid the best treatment? Is it underused in the U.S.?

The drug is the most effective way to cut the risk of severe disease. It's heading to China now. Yet the drug is underused in some places. Why? And are there options if you're not a good candidate?

The Conversation

RSV treatments for young children are lacking, but the record 2022 cold and flu season highlights the urgency for vaccines and other preventive strategies

For many parents, respiratory syncytial virus – or RSV – which has been causing record numbers of hospitalizations of children during the fall of 2022, may sound like a relatively new and unheard-of threat. But in fact, RSV is a common respiratory virus that circulates every fall and winter and…

Tribune News Service

Pfizer to sell Paxlovid in China as COVID cases surge

Pfizer Inc. cemented a deal first announced in March to sell its antiviral medication Paxlovid in China through a state-owned company, adding to supply of COVID treatments in the country that’s now facing a massive infection surge.

WEKU

2 years after Kentucky’s first COVID-19 vaccines, doctors continue to urge people to get vaxxed

Fortune

China has a new strategy for keeping official COVID numbers down during its reopening: Stop counting many new infections

With mandatory testing dropped, it can no longer accurately gauge the number of people who have COVID but don’t have symptoms, its National Health Commission said.

1 … 30 31 32 33

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.